First-cycle review failures costly, Parexel says
This article was originally published in Scrip
Executive Summary
Drug and biological applications that fail to gain US FDA approval during the first review cycle are increasingly likely to experience similar failures in subsequent cycles, a Parexel Consulting analysis has found.